India’s First Nationwide Childhood Cancer Survivorship Registry: 94.5% Survival, But Late Risks Remain

Summary

• India’s first nationwide registry on childhood cancer survivors (C2S cohort) reports a 94.5% five-year overall survival from diagnosis.
• The study covers 5,419 survivors from 20 centres, coordinated by AIIMS New Delhi.
• Event-free survival (no relapse or serious complications) at five years stands at 89.9%.
• Among children followed for at least two years after treatment, survival outcomes are even higher: 98.2% overall survival and 95.7% event-free survival.
• Despite strong survival, the study flags a significant risk of long-term health complications in survivors, echoing global evidence.
• Findings will help shape survivorship guidelines, multidisciplinary care, and health policy in India and similar low- and middle-income countries (LMICs).

---

1. What Is This Study About?

• Study title: “Long-term outcomes of the Indian childhood cancer survivorship C2S cohort: A multicentre study (2016–2024)”
• Published in: The Lancet Regional Health – Southeast Asia (February)
• Purpose:
  • Track how children fare after completing cancer treatment.
  • Measure both survival and long-term health issues (late effects).
  • Provide a strong data base for future research and policy.
• Lead bodies:
  • Initially developed by the Indian National Pediatric Oncology Group (2016).
  • Now overseen by the Indian Pediatric Hematology Oncology Group.
  • AIIMS New Delhi coordinates the project, data collection, and quality checks.

2. Who Was Included in the Registry?

• Total survivors enrolled: 5,419
• Survival data analysed: 5,140 children
• Inclusion criteria:
  • Children who had completed treatment.
  • Were declared in remission (no active cancer).
• Not included:
  • Children who relapsed.
  • Those who abandoned treatment.
  • Those who died early during or soon after treatment.
• Age at diagnosis:
  • 44% were between 2 and 8 years old.
• Gender and socio-economic profile:
  • Majority were boys.
  • Many came from families with modest income and lower educational backgrounds.
  • Large share treated in government hospitals.

3. Where Were These Children Treated?

• Number of centres: 20 across India.
• Major contributors:
  • AIIMS, New Delhi
  • Rajiv Gandhi Cancer Institute
  • Kidwai Memorial Institute of Oncology
  • Tata Memorial Hospital, Mumbai
  • Municipal Medical College & Hospital, Sion (Mumbai)

4. What Types of Cancers Were Most Common?

• Most common childhood cancers in the cohort:
  • Leukemia: 40.9%
  • Hodgkin lymphoma: 12.9%
  • Bone tumours: 8.4%
  • Retinoblastoma (eye cancer in children) – also significantly represented.

5. What Treatments Did Children Receive?

• Treatment modalities used:
  • Chemotherapy: 94.7%
  • Surgery: 30.3%
  • Radiotherapy: 26.3%

6. How Were Survivors Followed Up?

• Follow-up schedule:
  • Every 3 months for the first 2 years after treatment.
  • Every 6 months thereafter.
  • Follow-up was done in person or via phone.
• Key areas monitored:
  • Growth and puberty (physical development).
  • Schooling and educational progress.
  • Symptoms such as fatigue, cough, or emotional distress.
  • Family socio-economic status over time.

7. Key Survival Outcomes

7.1 Five-Year Outcomes from Diagnosis

• Overall survival (5 years): 94.5%
  • Meaning: About 95 out of 100 children were alive five years after diagnosis.
• Event-free survival (5 years): 89.9%
  • Meaning: Nearly 9 in 10 children had no relapse and no serious complications during this period.

7.2 Outcomes in Children Followed for at Least 2 Years After Treatment

• Number of survivors in this subgroup: 2,266
• Overall survival: 98.2%
• Event-free survival: 95.7%
• Implication:
  • Once children cross the first few years after completing treatment, their survival chances are extremely high.

8. Why Are Late Effects a Concern?

• The registry shows that children are surviving cancer in large numbers, but survival is not the end of the story.
• International research indicates:
  • One-third to one-half of childhood cancer survivors develop long-term complications.
  • Some late effects can be serious or life-threatening.
• Possible long-term complications include:
  • Heart problems (cardiotoxicity from certain drugs or radiotherapy).
  • Hormonal and endocrine disorders (growth issues, thyroid problems, fertility concerns).
  • Learning and cognitive difficulties (impacting school performance and daily functioning).
  • Emotional and psychological challenges (anxiety, depression, social adjustment issues).
• The study underlines a “hidden burden of survivorship” that may appear months or years after treatment ends.

9. Why Is This Registry Important for India and LMICs?

• The C2S cohort will serve as a denominator for future research on late effects in childhood cancer survivors.
• It will help in:
  • Developing India-specific survivorship care guidelines.
  • Designing multidisciplinary follow-up clinics (oncology, cardiology, endocrinology, psychology, etc.).
  • Informing health policy and resource allocation for survivorship care.
  • Guiding similar programmes in other low- and middle-income countries (LMICs).
• The study notes growing recognition of the need for cross-specialty, long-term care for childhood cancer survivors.

10. Key Takeaways

• India has achieved very high survival rates in childhood cancer in the centres studied, with five-year overall survival at 94.5%.
• Event-free survival is also strong, but not all survivors remain complication-free.
• Late effects are common worldwide, and India’s new registry is crucial to identifying and managing them in the local context.
• The C2S cohort will play a central role in:
  • Shaping clinical guidelines.
  • Improving quality of life for survivors.
  • Supporting evidence-based policymaking in childhood cancer care.

Source: Indian Express